litlas
Log inCreate account

Peter A. McSweeney

Active 1989–2024

67
Papers
22,043
Citations
56
h-index
66
i10-index

Citations

Citations per year for Peter A. McSweeney1948: 1 citations1985: 1 citations1992: 1 citations1996: 3 citations1997: 2 citations1999: 4 citations2000: 22 citations2001: 57 citations2002: 83 citations2003: 123 citations2004: 109 citations2005: 136 citations2006: 104 citations2007: 91 citations2008: 88 citations2009: 86 citations2010: 101 citations2011: 75 citations2012: 66 citations2013: 37 citations2014: 43 citations2015: 45 citations2016: 29 citations2017: 38 citations2018: 139 citations2019: 618 citations2020: 893 citations2021: 1,105 citations2022: 1,078 citations2023: 772 citations2024: 1,187 citations2025: 560 citations2026: 7 citations1949–1984: no citations, so these years are not shown1986–1991: no citations, so these years are not shown1993–1995: no citations, so these years are not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,964 citing papers, 31.6% of this breakdownChina: 737 citing papers, 7.9% of this breakdownGermany: 725 citing papers, 7.7% of this breakdownUnited Kingdom: 571 citing papers, 6.1% of this breakdownItaly: 512 citing papers, 5.5% of this breakdownFrance: 481 citing papers, 5.1% of this breakdownSpain: 368 citing papers, 3.9% of this breakdownCanada: 277 citing papers, 3% of this breakdownNetherlands: 261 citing papers, 2.8% of this breakdownSwitzerland: 235 citing papers, 2.5% of this breakdownAustralia: 204 citing papers, 2.2% of this breakdownJapan: 190 citing papers, 2% of this breakdown
0%31.6%Other 19.7%

Institutions

Fields

  • Medicine90.8%
  • Biochemistry, Genetics and Molecular Biology3.9%
  • Immunology and Microbiology3.6%
  • Engineering0.4%
  • Materials Science0.4%
  • Neuroscience0.2%
  • Other0.7%

Topics

  • CAR-T cell therapy research21.2%
  • Virus-based gene therapy research5.3%
  • Lymphoma Diagnosis and Treatment5.2%
  • Immune Cell Function and Interaction5.1%
  • Hematopoietic Stem Cell Transplantation5%
  • Nanowire Synthesis and Applications3.6%
  • Other54.6%

Coauthors

All papers

Open in search
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 cited by 5,915

  2. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    Authors: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Nöel Milpied, Henry C. Fung, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan - New England Journal of Medicine 2020 cited by 1,823

  3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    Authors: Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jaeyeon Kim, William Y. Go, Sattva S. Neelapu - The Lancet Oncology 2018 cited by 2,251

  4. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    Authors: Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok‐Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquín Martínez‐López, Antonia Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 cited by 520

  5. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    Authors: Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jaeyeon Kim, Yan Zheng, Frederick L. Locke - Blood 2023 cited by 228

  6. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

    Authors: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan - Journal of Clinical Oncology 2022 cited by 318

  7. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

    Authors: Olalekan O. Oluwole, Krimo Bouabdallah, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, André Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thiéblemont, John M. Timmerman, Patrick J. Stiff, Irit Avivi, Dimitrios Tzachanis, Jaeyeon Kim, Zahid Bashir, Jeff McLeroy, Yan Zheng, John M. Rossi, Lisa D. Johnson, Lovely Goyal, Tom van Meerten - British Journal of Haematology 2021 cited by 214

  8. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

    Authors: Keith Sullivan, Ellen Goldmuntz, Lynette Keyes-Elstein, Peter A. McSweeney, Ashley Pinckney, Beverly Welch, Maureen D. Mayes, Richard A. Nash, Leslie J. Crofford, Barry Eggleston, Sharon Castina, Linda M. Griffith, Julia Goldstein, Dennis Wallace, Oana Craciunescu, Dinesh Khanna, Rodney J. Folz, Jonathan Goldin, E. William St. Clair, James R. Seibold, Kristine Phillips, Shin Mineishi, Robert W. Simms, Karen K. Ballen, Mark H. Wener, George E. Georges, Shelly Heimfeld, Chitra Hosing, Stephen J. Forman, Suzanne Kafaja, Richard M. Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary Ellen Csuka, Christopher Bredeson, Carolyn A. Keever-Taylor, Robyn T. Domsic, M. Bashar Kahaleh, Thomas A. Medsger, Daniel E. Furst - New England Journal of Medicine 2018 cited by 589

  9. Ipilimumab for Patients with Relapse after Allogeneic Transplantation

    Authors: Matthew S. Davids, Haesook T. Kim, Pavan Bachireddy, Caitlin Costello, Rebecca Liguori, Alexandra Savell, Alexander Lukez, David Avigan, Yi‐Bin Chen, Peter A. McSweeney, Nicole R. LeBoeuf, Michael S. Rooney, Michaela Bowden, Chensheng W. Zhou, Scott R. Granter, Jason L. Hornick, Scott J. Rodig, Masahiro Hirakawa, Mariano Severgnini, F. Stephen Hodi, Catherine J. Wu, Vincent T. Ho, Corey Cutler, John Koreth, Edwin P. Alyea, Joseph H. Antin, Philippe Armand, Howard Streicher, Edward D. Ball, Jerome Ritz, Asad Bashey, Robert J. Soiffer - New England Journal of Medicine 2016 cited by 594

  10. Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

    Authors: Mohamed L. Sorror, Barry E. Storer, Brenda M. Sandmaier, David G. Maloney, Thomas R. Chauncey, Amelia Langston, Richard T. Maziarz, Michael A. Pulsipher, Peter A. McSweeney, Rainer Storb - Cancer 2008 cited by 262

  11. Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

    Authors: Mohamed L. Sorror, Brenda M. Sandmaier, Barry E. Storer, Georg‐Nikolaus Franke, Ginna G. Laport, Thomas R. Chauncey, Edward Agura, Richard T. Maziarz, Amelia Langston, Parameswaran Hari, Michael A. Pulsipher, Wolfgang Bethge, Firoozeh Sahebi, Benedetto Bruno, Michael B. Maris, Andrew M. Yeager, Finn Bo Petersen, Lars L. Vindeløv, Peter A. McSweeney, Kai Hübel, Marco Mielcarek, George E. Georges, Dietger Niederwieser, Karl G. Blume, David G. Maloney, Rainer Storb - JAMA 2011 cited by 320

  12. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

    Authors: Olalekan O. Oluwole, Édouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, André Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thiéblemont, John M. Timmerman, Patrick J. Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R. Shen, Harry Miao, Jaeyeon Kim, Tom van Meerten - Bone Marrow Transplantation 2024 cited by 25

  13. Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures

    Authors: Shervin Assassi, Xuan Wang, Guocai Chen, Ellen Goldmuntz, Lynette Keyes-Elstein, Binwu Ying, Paul K. Wallace, Jacob Turner, W. Jim Zheng, Virginia Pascual, John Varga, Monique Hinchcliff, Chiara Bellocchi, Peter A. McSweeney, Daniel E. Furst, Richard A. Nash, Leslie J. Crofford, Beverly Welch, Ashley Pinckney, Maureen D. Mayes, Keith M. Sullivan - Annals of the Rheumatic Diseases 2019 cited by 68

  14. Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation

    Authors: Burcu Ayoglu, Michele Donato, Daniel E. Furst, Leslie J. Crofford, Ellen Goldmuntz, Lynette Keyes-Elstein, Judith A. James, Susan Macwana, Maureen D. Mayes, Peter A. McSweeney, Richard A. Nash, Keith M. Sullivan, Beverly Welch, Ashley Pinckney, Rong Mao, Lorinda Chung, Purvesh Khatri, Paul J. Utz - Annals of the Rheumatic Diseases 2023 cited by 22

  15. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

    Authors: Peter A. McSweeney, Dietger Niederwieser, Judith A. Shizuru, Brenda M. Sandmaier, Arthur J. Molina, David G. Maloney, Thomas R. Chauncey, Theodore A. Gooley, Ute Hegenbart, Richard A. Nash, Jerald P. Radich, John L. Wagner, Steven T. Minor, Frederick R. Appelbaum, William Bensinger, Eileen Bryant, Mary E.D. Flowers, George E. Georges, F. Carl Grumet, Hans‐Peter Kiem, Beverly Torok‐Storb, Cong Yu, Karl G. Blume, Rainer Storb - Blood 2001 cited by 1,395

  16. A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies

    Authors: Michael Dickinson, Nada Hamad, Christian Bryant, Gautam Borthakur, Chitra Hosing, David Shook, Joanne B.L. Tan, Kanya Rajangam, Hongtao Liu, Glen Kennedy, Peter A. McSweeney, Brian T. Hill - Blood 2021 cited by 19

  17. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results

    Authors: James D. Bowen, George H. Kraft, Annette Wundes, Qingbo Guan, Kenneth R. Maravilla, Ted Gooley, Peter A. McSweeney, S.Ž. Pavletić, Harry Openshaw, R Storb, Mark H. Wener, B A McLaughlin, Gretchen Henstorf, RA Nash - Bone Marrow Transplantation 2011 cited by 82

  18. A randomized control trial of stress management for caregivers of stem cell transplant patients: Effect on patient quality of life and caregiver distress

    Authors: Mark L. Laudenslager, Teresa L. Simoneau, Susan K. Mikulich‐Gilbertson, Crystal Natvig, Benjamin W. Brewer, Timothy S. Sannes, Kristin Kilbourn, Jon Gutman, Peter A. McSweeney - Psycho-Oncology 2019 cited by 64

  19. Machine learning predicts stem cell transplant response in severe scleroderma

    Authors: Jennifer M. Franks, Viktor Martyanov, Yue Wang, Tammara Wood, Ashley Pinckney, Leslie J. Crofford, Lynette Keyes-Elstein, Daniel E. Furst, Ellen Goldmuntz, Maureen D. Mayes, Peter A. McSweeney, Richard A. Nash, Keith M. Sullivan, Michael L. Whitfield - Annals of the Rheumatic Diseases 2020 cited by 43

  20. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

    Authors: Michael Binks, Jakob Passweg, D E Furst, Peter A. McSweeney, Keith Sullivan, C. Besenthal, Jürgen Finke, HH Peter, JM van Laar, F C Breedveld, WE Fibbe, Dominique Farge, Éliane Gluckman, Franco Locatelli, Alberto Martini, F.H.J. van den Hoogen, Leo van de Putte, A Schattenberg, R. Arnold, P. A. Bacon, Paul Emery, Ildefonso Espigado, B. Hertenstein, Falk Hiepe, A. Kashyap, Ina Kötter, A Marmont, Alicia Martín Martínez, M J Espinosa Pascual, A Gratwohl, H. G. Prentice, C Black, Alan Tyndall - Annals of the Rheumatic Diseases 2001 cited by 285

  21. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.

    Authors: Wendy Osborne, Maria A. V. Marzolini, Eleni Tholouli, Aravind Ramakrishnan, Carlos Bachier, Peter A. McSweeney, David Irvine, Michael Zhang, Muhammad Al‐Hajj, Martin Pulé, Simon Thomas, Maud Jonnaert, Vijay Gopal Reddy Peddareddigari, Nushmia Z. Khokhar, Robert W. Chen, Kirit M. Ardeshna - Journal of Clinical Oncology 2020 cited by 45

  22. Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

    Authors: Mohamed L. Sorror, Barry E. Storer, Brenda M. Sandmaier, Michael B. Maris, Judith A. Shizuru, Richard T. Maziarz, Edward Agura, Thomas R. Chauncey, Michael A. Pulsipher, Peter A. McSweeney, James C. Wade, Benedetto Bruno, Amelia Langston, Jerald P. Radich, Dietger Niederwieser, Karl G. Blume, Rainer Storb, David G. Maloney - Journal of Clinical Oncology 2008 cited by 278

  23. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study

    Authors: Christian Junghanß, Kieren A. Marr, Rachel A. Carter, Brenda M. Sandmaier, Michael B. Maris, David G. Maloney, Thomas R. Chauncey, Peter A. McSweeney, Rainer Storb - Biology of Blood and Marrow Transplantation 2002 cited by 253

  24. Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors

    Authors: Ute Hegenbart, Dietger Niederwieser, Brenda M. Sandmaier, Michael B. Maris, Judith A. Shizuru, Hildegard Greinix, Catherine Cordonnier, Bernard Rio, Aloïs Gratwohl, Thoralf Lange, Haifa Kathrin Al‐Ali, Barry E. Storer, David G. Maloney, Peter A. McSweeney, Thomas R. Chauncey, Ed Agura, Benedetto Bruno, Richard T. Maziarz, Finn Bo Petersen, Rainer Storb - Journal of Clinical Oncology 2005 cited by 250